Correction to: Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta‑analysis

被引：0
|
作者：
Fenghua Gao
Tingting Zhang
Hengqi Liu
Wei Li
Xianming Liu
Lihua Qiu
Lanfang Li
Shiyong Zhou
Zhengzi Qian
Sitong Dong
Sai Zhao
Xianhuo Wang
Huilai Zhang
机构：
[1] the Sino-US Center for Lymphoma and Leukemia Research,Department of Lymphoma, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin’s Clinical Researc
[2] The Ingenuity Centre,Systematic Review Solutions Ltd
来源：
Annals of Hematology | 2022年 / 101卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2817 / 2817
相关论文
共 50 条
  • [11] Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death
    Sortais, C.
    Lok, A.
    Gastinne, T.
    Mahe, B.
    Dubruille, V.
    Blin, N.
    Howlett, S.
    Tabah, A.
    Arnaud, P.
    Moreau, A.
    Moreau, P.
    Leux, C.
    Le Gouill, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 364 - 364
  • [12] Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.
    Casulo, Carla
    Larson, Melissa C.
    Day, Jonathan R.
    Habermann, Thomas Matthew
    Lossos, Izidore S.
    Wang, Yucai
    Nastoupil, Loretta J.
    Strouse, Christopher
    Chihara, Dai
    Martin, Peter
    Cohen, Jonathon Brett
    Kahl, Brad S.
    Ruan, Jia
    Burack, Walter Richard
    Koff, Jean Louise
    Friedberg, Jonathan W.
    Cerhan, James Robert
    Flowers, Christopher
    Link, Brian K.
    Maurer, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [13] Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort
    Marie Hairing Enemark
    Jonas Klejs Hemmingsen
    Maja Dam Andersen
    Trine Engelbrecht Hybel
    Mads Emil Bjørn
    Pär Lars Josefsson
    Lars Møller Pedersen
    Maja Bech Juul
    Robert Schou Pedersen
    Michael Thorsgaard
    Ida Blok Sillesen
    Trine Lindhardt Plesner
    Stephen Jacques Hamilton-Dutoit
    Paw Jensen
    Charlotte Madsen
    Maja Ludvigsen
    Blood Cancer Journal, 14 (1)
  • [14] Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
    Merryman, Reid
    Belada, David
    Sureda, Anna
    Leppa, Sirpa
    Vermaat, Joost S. P.
    Holte, Harald
    Hutchings, Martin
    Lugtenburg, Pieternella
    de Vos, Sven
    Abrisqueta, Pau
    Nijland, Marcel
    Christensen, Jacob Haaber
    Wahlin, Bjorn E.
    Linton, Kim M.
    Wang, Liwei
    Abbas, Aqeel
    Rana, Ali
    Quadri, Syed
    Falchi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [15] External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse
    Boyne, Devon J.
    Chua, Neil
    Owen, Carolyn
    Joe-Uzuegbu, Ofodile
    Shakir, Huma
    Gogna, Priyanka
    Jarada, Tamer N.
    Brenner, Darren R.
    Elia-Pacitti, Julia
    Ewara, Emmanuel M.
    Cheung, Winson Y.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09): : e277 - e285
  • [16] A systematic review and meta-analysis of occupational exposures and risk of follicular lymphoma
    Odutola, Michael K.
    Benke, Geza
    Fritschi, Lin
    Giles, Graham G.
    van Leeuwen, Marina T.
    Vajdic, Claire M.
    ENVIRONMENTAL RESEARCH, 2021, 197
  • [17] in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses
    Czerwinski, Debra K.
    Brody, Joshua
    Kohrt, Holbrook E.
    Hoppe, Richard T.
    Advani, Ranjana H.
    Levy, Ronald
    BLOOD, 2012, 120 (21)
  • [18] A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
    Hicks, Lisa K.
    Haynes, Adam E.
    Reece, Donna E.
    Walker, Irwin R.
    Herst, Jordan A.
    Meyer, Ralph M.
    Imrie, Kevin
    CANCER TREATMENT REVIEWS, 2008, 34 (05) : 442 - 452
  • [19] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Sortais, Clara
    Lok, Anne
    Tessoulin, Benoit
    Gastinne, Thomas
    Mahe, Beatrice
    Dubruille, Viviane
    Blin, Nicolas
    Touzeau, Cyrille
    Moreau, Anne
    Bossard, Celine
    Peterlin, Pierre
    Garnier, Alice
    Guillaume, Thierry
    Le Bourgeois, Amandine
    Chevallier, Patrice
    Moreau, Philippe
    Leux, Christophe
    Le Gouill, Steven
    ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1595 - 1604
  • [20] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
    Clara Sortais
    Anne Lok
    Benoit Tessoulin
    Thomas Gastinne
    Béatrice Mahé
    Viviane Dubruille
    Nicolas Blin
    Cyrille Touzeau
    Anne Moreau
    Céline Bossard
    Pierre Peterlin
    Alice Garnier
    Thierry Guillaume
    Amandine Le Bourgeois
    Patrice Chevallier
    Philippe Moreau
    Christophe Leux
    Steven Le Gouill
    Annals of Hematology, 2020, 99 : 1595 - 1604
12345